BIOA
BioAge Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.59
+0.95%Year over year
Reported trailing growth
- Revenue
- +168.1%
- EBITDA
- -20.9%
- EBIT
- -16.4%
- EPS
- +75.3%
- Free cash flow
- -51.1%
- Operating cash flow
- -52.6%
Forward estimates
Based on analyst estimates
- Revenue
- -69.6%
- EBITDA
- -9.8%
- EPS
- +2.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -16.2%
- EBIT
- -18.7%
- Net income
- -13.4%
- EPS
- -13.1%
- Free cash flow
- -58.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026